Enhancement Potential for a Classical Batch-Mode Upstream Measles Process*: Impact of AggreGuard™
AggreGuard™, a CellRev product, was independently evaluated in a commercially relevant measles vaccine process without altering standard operating protocol, showing:
- ↓ cell-to-cell adhesion and ↑ cell culture homogeneity.
- ↓ glucose/glutamine consumption and ↓ lactate/ammonia production.
- ↑ viral infection kinetics and ↓ time to peak viral titre
- Up to 8% cost reduction in upstream manufacturing per 1L per day
Download the full report below.
